Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

L. Dorrell; C. A. O'Callaghan; W. Britton; S. Hambleton; A. McMichael; G. L. Smith; S. Rowland-Jones; T. J. Blanchard

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

L. Dorrell, C. A. O'Callaghan, W. Britton, S. Hambleton, A. McMichael, G. L. Smith, S. Rowland-Jones, T. J. Blanchard

Research output: Contribution to journal › Article › peer-review

Abstract

The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity for known NP epitopes. These CTL efficiently lysed NP peptide- pulsed targets and released interferon-γ (IFN-γ) on contact with epitope peptide. MVA-NP-stimulated CTL specific for the HLA-B8 epitope, NP380-88, stained with a tetrameric complex of HLA-B8 refolded with the NP380-88 peptide and anti-CD8 antibody on flow cytometry. CTL were also elicited from two HIV-1 seropositive donors by restimulation with MVA-HIV-1 gag and showed specificity for immunodominant gag epitopes. These data indicate that restimulation of human CTL with recombinant MVA is effective and suggest that MVA will elicit CTL responses in humans in vivo. (C) 2000 Elsevier Science Ltd.

Original language	English
Pages (from-to)	327-336
Number of pages	9
Journal	Vaccine
Volume	19
Issue number	2-3
Publication status	Published - 15 Sept 2000

Keywords

Cytotoxic T lymphocyte
MVA strain
Vaccinia virus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{19ec861f339b419e9bdc414d39705c50,

title = "Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro",

abstract = "The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity for known NP epitopes. These CTL efficiently lysed NP peptide- pulsed targets and released interferon-γ (IFN-γ) on contact with epitope peptide. MVA-NP-stimulated CTL specific for the HLA-B8 epitope, NP380-88, stained with a tetrameric complex of HLA-B8 refolded with the NP380-88 peptide and anti-CD8 antibody on flow cytometry. CTL were also elicited from two HIV-1 seropositive donors by restimulation with MVA-HIV-1 gag and showed specificity for immunodominant gag epitopes. These data indicate that restimulation of human CTL with recombinant MVA is effective and suggest that MVA will elicit CTL responses in humans in vivo. (C) 2000 Elsevier Science Ltd.",

keywords = "Cytotoxic T lymphocyte, MVA strain, Vaccinia virus",

author = "L. Dorrell and O'Callaghan, {C. A.} and W. Britton and S. Hambleton and A. McMichael and Smith, {G. L.} and S. Rowland-Jones and Blanchard, {T. J.}",

year = "2000",

month = sep,

day = "15",

language = "English",

volume = "19",

pages = "327--336",

journal = "Vaccine",

issn = "1873-2518",

publisher = "Elsevier BV",

number = "2-3",

}

TY - JOUR

T1 - Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

AU - Dorrell, L.

AU - O'Callaghan, C. A.

AU - Britton, W.

AU - Hambleton, S.

AU - McMichael, A.

AU - Smith, G. L.

AU - Rowland-Jones, S.

AU - Blanchard, T. J.

PY - 2000/9/15

Y1 - 2000/9/15

N2 - The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity for known NP epitopes. These CTL efficiently lysed NP peptide- pulsed targets and released interferon-γ (IFN-γ) on contact with epitope peptide. MVA-NP-stimulated CTL specific for the HLA-B8 epitope, NP380-88, stained with a tetrameric complex of HLA-B8 refolded with the NP380-88 peptide and anti-CD8 antibody on flow cytometry. CTL were also elicited from two HIV-1 seropositive donors by restimulation with MVA-HIV-1 gag and showed specificity for immunodominant gag epitopes. These data indicate that restimulation of human CTL with recombinant MVA is effective and suggest that MVA will elicit CTL responses in humans in vivo. (C) 2000 Elsevier Science Ltd.

AB - The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity for known NP epitopes. These CTL efficiently lysed NP peptide- pulsed targets and released interferon-γ (IFN-γ) on contact with epitope peptide. MVA-NP-stimulated CTL specific for the HLA-B8 epitope, NP380-88, stained with a tetrameric complex of HLA-B8 refolded with the NP380-88 peptide and anti-CD8 antibody on flow cytometry. CTL were also elicited from two HIV-1 seropositive donors by restimulation with MVA-HIV-1 gag and showed specificity for immunodominant gag epitopes. These data indicate that restimulation of human CTL with recombinant MVA is effective and suggest that MVA will elicit CTL responses in humans in vivo. (C) 2000 Elsevier Science Ltd.

KW - Cytotoxic T lymphocyte

KW - MVA strain

KW - Vaccinia virus

M3 - Article

SN - 1873-2518

VL - 19

SP - 327

EP - 336

JO - Vaccine

JF - Vaccine

IS - 2-3

ER -

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

Abstract

Keywords

UN SDGs

Fingerprint

Cite this